AUSTIN, TEXAS / ACCESS Newswire / July 8, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) (“Monogram” or the “Company”), an ...

Ben Sexson, Monogram CEO, stated, "This FDA 510(k) clearance is a defining moment for Monogram. It marks the culmination of years of relentless effort, innovation, and teamwork.

Monogram Technologies Announces FDA 510(k) Clearance for the Monogram mBôsTM TKA System ACCESS Newswire. March 17, 2025 7:20 AM. Monogram May Market the Monogram mBôs™ TKA System, Subject to ...

By Thomas Kerr, CFA NASDAQ:MGRM READ THE FULL MGRM RESEARCH REPORT FDA Response to 510(k) Filing On October 6, 2024, Monogram (NASDAQ:MGRM) announced it had received an Additional Information ...

The Application was submitted on July 19, 2024, and passed the initial FDA Administrative Review. On September 30, 2024, Monogram received an Additional Information Request ("AIR") from the FDA.

Monogram Technologies Submits 510(k) Application for mBôs TKA System Clearance ACCESSWIRE. Updated August 08, 2024 8:16 AM. Application was Submitted on July 19, 2024, Passed the FDA ...

Ben Sexson, Monogram Chief Executive Officer, commented, "This FDA 510(k) clearance is a defining moment for Monogram. It marks the culmination of years of relentless effort, innovation, and teamwork.

FDA Decision is Expected Within 90 Days of Initial Submission; However, the Process May be Paused if Additional Information is Requested AUSTIN, TX / ACCESSWIRE / August 8, 2024 / Monogram ...